Pembrolizumab Administered Via the Sofusa® DoseConnect™ in Patients With Relapsed/Refractory Cutaneous T-cell Lymphoma.

Exclusion Criteria

• •Disease with extensive visceral or blood involvement.
• •Previously treated with an anti-PD-L1 or anti-PD-1 antibody
• •Any active autoimmune disease or a documented history of autoimmune disease, or history of syndrome that required systemic steroids or immunosuppressive medications, except for participants with vitiligo, hormone replacement therapy for stable thyroid diseases and Type 1 diabetes mellitus.
• •Prior allogeneic hematopoietic stem cell transplantation (HSCT) or solid organ transplantation.
• •Known seropositive for or have active infection with hepatitis C virus (HCV) or hepatitis B virus (HBV), or human immunodeficiency virus (HIV)
• •History of interstitial lung disease
• •History of severe hypersensitivity reactions to other monoclonal antibodies or known hypersensitivity to the study intervention or its excipients, indocyanine green dye or iodine.
• •Known current drug or alcohol abuse.
• •Pregnant or lactating.
• •Underlying medical condition resulting in abnormally slow lymphatic flow as determined by the Investigator.
• •Require immediate treatment for MF